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Background: Malignant pleural mesothelioma (MPM) is a rare but
aggressive asbestos-related cancer that develops by mesothelial cell
transformation. At present, there are no effective therapies for MPM.
Great efforts have been made in finding specific markers/mecha-
nisms for MPM onset, including studies into microRNAs (miR-
NAs). Recent studies have shown the differential expression of
mature miRNAs in several human cancers, suggesting their potential
role as oncogenes or tumor suppressor genes.
Methods: In this study, we investigated miRNAs profile in five
human normal pleural mesothelial short-term cell cultures (HMCs)
and five MPMs, with microarray approach. These results were
confirmed by real-time quantitative reverse-transcriptase polymer-
ase chain reaction and Western blotting.
Results: A comparative analysis of miRNA expression in MPM and
HMCs was carried out. Microarray profiling showed different
miRNA expression between MPM and HMCs. Specifically, mem-
bers of the oncomiRNA miR 17-92 cluster and its paralogs, namely
miR 17-5p, 18a, 19b, 20a, 20b, 25, 92, 106a, 106b, were markedly
upregulated. Besides, in our investigation, additional miRNAs, such
as miR-7, miR-182, miR-214, and miR-497 were found to be dys-
regulated in MPM.
Conclusions: These data are in agreement with results that have
previously been reported on dysregulated miRNAs for other solid
human tumors. Moreover , in our investigation, additional miRNAs
were found to be dysregulated in MPM. Interestingly, gene products
that regulate the cell cycle are targets and predicted targets for these
miRNAs. Our data suggest that specific miRNAs could be key
players in MPM development/progression. In addition, some of
these miRNAs may represent MPMmarkers and potential targets for
new therapeutic approaches.
Key Words: MicroRNAs, Microarray, Mesothelioma, Gene target
analysis.
(J Thorac Oncol. 2011;6: 844–851)
Human malignant pleural mesothelioma (MPM) is anaggressive tumor which develops by pleural mesothelial
cell transformation.1 MPM incidence is expected to rise in
forthcoming decades.2 MPM is characterized by a rapid
increase in tumor mass, which induces death as a result of
heart and lung compression without metastatization.3 Expo-
sure to asbestos is a well-known risk factor, whereas acti-
vated oncogenes, genetic predisposition, and SV40 infection
have also been proposed as cofactors.4 The asbestos carcino-
genesis mechanism has been linked to proinflammatory cy-
tokines and nuclear factor-B activation.5,6 Moreover, there
is evidence that the malignant transformation of mesothelial
cells, on exposure to asbestos fibers, also occurs through Akt
activation by phosphorylation.7,8 Recently, it has been dem-
onstrated that A3 adenosine receptor (A3ARs) mediated a
reduction of Akt phosphorylation and nuclear factor-B ac-
tivation in MPM cell lines. Furthermore, A3AR stimulation
decreased proliferation and increased apoptosis in MPM-
derived cells and in human normal pleural mesothelial short-
term cell cultures (HMCs) exposed to asbestos and tumor
necrosis factor-, but not in untreated HMCs, suggesting that
A3AR could represent a novel target for therapeutic interven-
tion in MPM.9
At present, there are no effective therapies for MPM
and patients die in approximately 1 year. Therefore, knowl-
edge on the major molecular pathways involved in MPM
onset/progression is necessary to define appropriate targets
for the treatment of this disease.
One of the most recent advances in cancer research has
involved microRNAs (miRNAs or miRs). miRNAs represent
a family of small noncoding RNAs (approximately 21–25 nt
long), which are expressed in many organisms including
animals, plants, and viruses.10 miRNAs negatively regulate
gene expression by modulating target mRNA translation
efficiency and are integral to many cellular processes includ-
ing development, differentiation, proliferation, apoptosis, and
stress response.11 Previous studies have demonstrated that
miRNA expression profiles can be used to classify several
human cancers12 and have identified abnormal miRNA ex-
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pression in several types of malignancies, both hematopoietic
and solid tumors, emphasizing their functions as oncogenes
and tumor suppressor genes.13,14 In particular, the mir-17-92
onco-miRNA cluster has been shown to be involved in
several tumors. In humans, this family includes 15 homolo-
gous miRNAs, which are encoded by three gene clusters
mapping on chromosome 7, 13, and X.15,16 The role of this
cluster in oncogenesis has been demonstrated with a great
deal of evidence: (1) its overexpression in different types of
malignancies14; (2) its amplification in human B-cell lympho-
mas17; and (3) an up-regulation in small-cell lung cancer, and
its ectopic overexpression which enhances lung cancer cell
growth.18,19
Recent data indicate that miRNAs may be used as
diagnostic markers for cancers, including the MPM20,21 and
could correlate closely with patient survival and with several
clinical-pathologic factors.22 Moreover, it has been shown
that miR-29c* is an independent prognostic factor in MPM
for time to progression and survival after surgical cytoreduc-
tion. Higher level of this miR is detected in epithelial MPM
and associated with greater survival of patients. MiR-29c*
affects gene methylation and other pathways up-regulated in
MPM.23 In addition, it has been suggested that tumor-sup-
pressive activity of miR-31 can be used for development of
new therapies against MPM. It has been shown that the
reintroduction of miR-31, in MPM cell lines incapable to
express miR-31 due to loss of the 9p21.3, suppressed the cell
cycle and inhibited expression of multiple factors involved in
cooperative maintenance of DNA replication and cell cycle
progression, including prosurvival phosphatase PPP6C,
which was previously associated with chemotherapy and
radiation therapy resistance, and maintenance of chromo-
somal stability.24
Therefore, identifying miRNA signature expressions
between tumor and normal cells is important in investigat-
ing the specific roles different miRNAs have in tumor
development and identifying the genes and pathways tar-
geted by them.
Herein, we report on the comparative analysis of
miRNA expression in MPM and HMC, and the identification
of new dysregulated miRNA in MPM. The aim of this
investigation was (1) to obtain new knowledge on MPM
onset/progression, (2) to reveal new MPM-specific markers,
and (3) to find MPM targets for potential innovative thera-
peutic approaches.
PATIENTS AND METHODS
Cells
HMCs (4N, 6N, 13N, 16N, and 26N) were obtained
from biopsies, collected from young nononcologic patients
from at the Surgical Clinic of the University/Hospital, Ferrara
(see Supplemental Table S1 for clinical data). These cell lines
were established in vitro as reported before.9,25–28 Five MPM
cell lines were purchased from cell repositories. MSTO-
211H, MPP-89, and IST-MES229,30 were obtained from the
GMP Cells and Cultures Bank, National Cancer Institute,
Genoa, Italy, whereas NCI-H2052 and NCI-H2831 were pur-
chased from American Type Culture Collection, Manassas,
VA. TP53wild-type SKW6.4 cell line,32 treated with Nutlin,
and HeLa cell line33 were used as a positive control in
Western blotting analysis, for p21 and GAPDH, respectively.
HMCs, MSTO-211 H, NCI-H2052, NCI-H28, and TP53wild-type
SKW6.4 were grown in the Roswell Park Memorial Institute
(culture medium) 1640, 10% fetal bovine serum, 2 mM
L-Glutamine, whereas IST-MES2, MPP89, and HeLa in D-
MEM Ham’s F12, 10% fetal bovine serum (Lonza, Basel,
Switzerland).
RNA Samples
The total RNA was isolated from the HMC and MPM
samples using Eurozol solution (Euroclone, Milan, Italy)
following the manufacturer’s protocol. In brief, 5  106 cells
were suspended in 1 ml of Eurozol solution added to 100 l
of chloroform. Then, the RNA was precipitated using isopro-
panol solution and resuspended in RNAse-free H2O. Be-
fore hybridization, RNAs were inspected and quantified
using a spectophotometric reading (Bioanalyzer, Agilent,
Palo Alto, CA).
miRNA and Gene Expression Analysis by
Microarray
MiRNA expression profiling for five HMCs and five
MPMs was carried out on Agilent Human microRNA mi-
croarray (G4470A, Agilent Technologies, Palo Alto, CA).
This microarray consists of 60-mer DNA probes synthesized
in situ, which represent 470 human and 64 human viral
miRNAs from the Sanger database (release 9.1). One-color
miRNAs labeling, hybridization and washing was performed
in accordance with the manufacturer’s procedure.
RNA from the same 10 samples was also hybridized on
the Agilent whole human genome microarray (Agilent Tech-
nologies, Palo Alto, CA). This microarray consists of 60-mer
DNA probes which have been synthesized in situ, and rep-
resent 41,000 unique human transcripts. One-color gene ex-
pression was performed according to the manufacturer’s
procedure. Briefly, a total RNA fraction was obtained from
samples using Eurozol solution (Euroclone, Milan, Italy).
RNA quality was assessed using the Agilent 2100 Bioana-
lyzer (Agilent Technologies, Palo Alto, CA). Low quality
RNAs (RNA integrity number 7) were excluded from the
microarray analyses. Labeled cRNA was synthesized from
500 ng of the total RNA using the Low RNA Input Linear
Amplification Kit (Agilent Technologies) in the presence of
cyanine 3-CTP (Perkin-Elmer Life Sciences, Boston, MA).
Hybridizations were performed at 65°C for 17 hours in a
rotating oven. Five-micrometer resolution images were gen-
erated using an Agilent scanner and Feature Extraction ver-
sion 9.5 software (Agilent Technologies) was used to obtain
the microarray raw data.
Data Analysis
The microarray results were analyzed using Gene-
Spring GX software (Agilent Technologies). Data files were
preprocessed using the GeneSpring plug-in for Agilent Fea-
ture Extraction software results. Data transformation was
applied to set all the negative raw values at 0.01, followed by
on-chip and on-gene median normalization. A filter on low
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gene expression was used so that only the probes expressed
(flagged as Present) in at least one sample were kept; the
probes which remained unchanged between samples, and
were identified as having an expression value across all
samples with a median of 1.5 were removed. Then, the
samples were grouped into tumors and controls and com-
pared. Differentially expressed genes were selected as having
a twofold expression difference between their geometrical
mean in the two groups and a statistically significant p value
(0.05) using the analysis of variance statistic, then the
Benjamini and Hoechberg correction for false positives re-
duction was applied.
Differentially expressed genes were used for a Cluster
Analysis of samples, using the Pearson correlation as a
measure of similarity.
Real-Time Reverse-Transcriptase Polymerase
Chain Reaction
A real-time quantitative reverse-transcriptase polymer-
ase chain reaction (RT-qPCR) was used to validate microar-
ray data for four miRNAs, namely miR-17-5p, miR-20a,
miR-92, and miR-497. TaqMan MicroRNA Assays Kits were
purchased from Applied Biosystems (Foster City, CA). U6
RNA (RNU6B, N/P: 4373381; Applied Biosystems) was used
as a normalization reference. Kits were used in accordance
with the manufacturer’s instructions. RNAs were diluted at 2
ng/l in DEPC-water and 10 ng were used as a template in
each reverse-transcription reaction. The subsequent quantita-
tive PCR was carried out in triplicate for each sample for both
the RNU6B control and each miRNA. Reactions were per-
formed on the Applied biosystems 7500 real time thermal
cycler, using the following conditions: 10 minutes at 95°C for
enzyme activation, followed by 40 cycles, consisting of 15
seconds at 95°C and 1 minute at 60°C. miRNA expression
level was measured using the Ct method, where the Ct
(threshold cycle) is the fractional cycle number when the
fluorescence of each sample passes a fixed threshold and
Ct (CtmiR CtRNU6B)sample (CtmiR CtRNU6B)control.
The miRNA relative fold change was determined using the
2Ct method.
Western Blotting
Cell lysates from HMC and MPM cells were prepared
using a dysruption buffer (glycerol 40%, sodium dodecyl
sulfate 2%, 2 -mercaptoethanol 5%, Tris-HCl 60 mM,
phosphate-buffered saline 1, and protease inhibitor cock-
tail). Two HMCs, 4N and 6N, and 5 MPMs, MSTO-211H,
MPP89, IST-MES2, NCI-H28, and NCI-H2052, the same
cell lines analyzed in microarray, were investigated by West-
ern blotting. The protein (40 g) was loaded onto a 12%
sodium dodecyl sulfate polyacrylamide gel then transferred
onto nitrocellulose membranes and blocked for 1 hour at
room temperature with 5% nonfat dry milk in tris-buffered
saline-Tween. Blots were incubated with the antibody against
p21, diluted 1:200 (clone DCS-60, Santa Cruz Biotech., Santa
Cruz, CA) overnight at 4°C, followed by incubation with
horseradish peroxidase-conjugated secondary anti mouse IgG
(Santa Cruz Biotech.) for 1 hour at room temperature. Protein
bands were visualized with ECL solution (GE Healthcare,
Milan, Italy) following the manufacturer’s instructions. Pro-
tein bands were normalized with the GAPDH protein ob-
tained with the specific MAB, and diluted 1:1000 (clone
0411, Santa Cruz Biotech.).
RESULTS
Comparative Analysis of miRNA Expression in
MPM and HMC Samples
MPM and HMC RNA samples were comparatively
analyzed for miRNA expression. To this end, isolated RNAs
were investigated using a microarray approach (Agilent
Technologies, Human miRNA microarray G4470A). Data
from the analysis showed miRNA expression dysregulation
in MPM when compared with HMC samples. Indeed, 151
miRNAs were found to exhibit more than a twofold change
when the average MPMs expression was compared with that
of the HMCs. Among these 151 miRNAs, 22 (14 overex-
pressed and 8 down-regulated) exhibited a statistically sig-
nificant difference (analysis of variance p  0.05, Benjamini
and Hochberg correction) (Table 1). Cluster analysis using
these 22 miRNAs confirmed their ability to separate MPM
and HMC samples (Figure 1).
To validate the microarray analysis results, four of the
modulated miRNAs were further analyzed using RT-qPCR.
Specifically, we selected three miRNA samples, namely miR-
17-5p, miR-20a, and miR-92, which are up-regulated and one
miRNA, miR-497, which is down-regulated. It is of interest
to note that miR-497 had already been reported as being
down-regulated in other lung malignancies34 and in primary
peritoneal carcinoma.35 RT-qPCR analysis confirmed
miRNA expression differences between MPM and HMC
samples (Figure 2).
Target Modulation in MPM
The same samples were also hybridized on a whole
human genome microarray (Agilent Technologies), which
was able to assess the expression of 41,000 transcripts, to
specifically evaluate the expression of miRNA validated
targets. Gene expression data analysis showed an inverse
correlation between the selected miRNAs and many of their
validated targets (source: Tarbase)36 (Table 2). Because some
human miRNAs exert their action by inducing target mRNA
cleavage, these observations support the role of selected
miRNAs as gene expression regulators. That notwithstand-
ing, some target genes do not display regulation at mRNA
level, which can be explained by miRNA action only on
protein translation37 or by the concomitant action of several
other miRNAs on the same target.
p21 Is Down-Regulated in MPM
CDKN1A/p21 is a potent negative regulator of the
G1-S checkpoint. It has been shown to be a miR 17-92 cluster
target15 and its mRNA levels were found to be down-regu-
lated in our MPM samples. To validate our microarray data,
five MPM and two HMC samples, were investigated for p21
expression using the Western blot technique. We reasoned
that an absence of p21 expression could be due to the
overexpression of the miRNAs belonging to the miR 17-92
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cluster and its cluster paralog in MPM samples. In HMCs,
p21 is normally expressed (Figure 3), whereas its expression
is absent or reduced in MPM samples (Figure 3). This
reduction could be the effect of the miR 17-92 cluster up-
regulation which had been observed in MPM samples.
DISCUSSION
Our miRNA expression profile identified a group of 22
miRNAs, which were significantly dysregulated by compar-
ing MPM versus HMC short-term cell lines. RT-qPCR and
Western blotting analysis confirmed the microarray results. In
our study, miRNAs which have been linked to oncogenesis as
members of the onco-miRNA miR-17-92 clusters, were
markedly up-regulated in MPM samples (Table 1), suggest-
ing their importance in tumor development. These data are in
agreement with results previously which have been reported
for other solid tumors,14 including mesothelioma.38 MiR-20b,
miR-25, miR-106a, and miR-106b, which belong to the miR-
17-92 cluster paralogs were also found to be up-regulated in
our MPM samples.
The miR-17-92 cluster is induced by the oncogene
c-Myc,39 thus acting as a Myc effector. Moreover, the en-
forced expression of the miR-17-92 cluster was proven to
functionally act together with c-Myc to accelerate tumor
development in a mouse B-cell lymphoma model,40 thus
acting as an antiapoptotic oncogene. At the molecular level,
this function is mediated by the targeting and inhibition of
proapoptotic protein coding genes. Among these, E2F1,
E2F2, and E2F3, which are critical regulators of cell cycle
and apoptosis, were verified as targets of miR-17-92 and
miR-106b-25 clusters.13,39,41,42 Specially, E2F1 and E2F3 can
directly activate the transcription of these miRNA, establish-
ing a negative feedback loop. Given that high levels of E2F1
can induce apoptosis, this negative feedback may dampen
TABLE 1. MicroRNAs Differentially Expressed Between MPM and HMCs
miRNA miRNA Cluster Chromosome Start . . . End (strand)
Expression
pa MPM HMC
Fold Change
Ratio
hsa-miR-182 mir-183 - mir-96 - mir-182 7 129197459 . . . 129197568 () 0.012 2.97 0.01 297.0
hsa-miR-502 mir-500 - mir-362 - mir-501 - mir-660
- mir-502
X 49665946 . . . 49666031 () 0.012 0.01 0.28 0.04
hsa-miR-497 mir-497 - mir-195 17 6861954 . . . 6862065 () 0.023 0.01 0.06 0.17
hsa-miR-146b — 10 104186259 . . . 104186331 () 0.028 0.03 1.33 0.02
hsa-miR-17-5p mir-17 - mir-18a - mir-19a - mir-20a -
mir-19b-1 - mir-92a-1
13 90800860 . . . 90800943 () 0.033 20.74 3.35 6.19
hsa-miR-7 — 9 85774483 . . . 85774592 () 0.033 0.78 0.17 4.59
hsa-miR-92a-1 mir-17 - mir-18a - mir-19a - mir-20a -
mir-19b-1 - mir-92a-1
13 90801569 . . . 90801646 () 0.033 76.43 18.34 4.17
hsa-miR-92a-2 mir-106a - mir-18b - mir-20b - mir-
19b-2 - mir-92a-2 - mir-363
X 133131234 . . . 133131308 () 0.033 76.43 18.34 4.17
hsa-miR-33 — 22 40626894 . . . 40626962 () 0.033 1.64 0.4 4.10
hsa-miR-328 — 16 65793725 . . . 65793799 () 0.033 0.01 0.14 0.07
hsa-miR-214 mir-199a-2 - mir-214 1 170374561 . . . 170374670 () 0.033 0.04 36.1 0.001
hsa-miR-196b — 7 27175624 . . . 27175707 () 0.036 0.57 0.03 19.0
hsa-miR-20a mir-17 - mir-18a - mir-19a - mir-20a -
mir-19b-1 - mir-92a-1
13 90801320 . . . 90801390 () 0.036 59.60 8.78 6.79
hsa-miR-106a mir-106a - mir-18b - mir-20b - mir-
19b-2 - mir-92a-2 - mir-363
X 133131894 . . . 133131974 () 0.036 51.48 9.15 5.63
hsa-miR-20b mir-106a - mir-18b - mir-20b - mir-
19b-2 - mir-92a-2 - mir-363
X 133131505 . . . 133131573 () 0.037 3.80 0.55 6.91
hsa-miR-18a mir-17 - mir-18a - mir-19a - mir-20a -
mir-19b-1 - mir-92a-1
13 90801006 . . . 90801076 () 0.037 6.75 1.03 6.55
hsa-miR-339 — 7 1029095 . . . 1029188 () 0.037 3.97 1.11 3.58
hsa-miR-106b mir-106b - mir-93 - mir-25 7 99529552 . . . 99529633 () 0.037 16.65 5.35 3.11
hsa-miR-22 — 17 1563947 . . . 1564031 () 0.037 94.08 262.94 0.36
hsa-miR-549 — 15 78921374 . . . 78921469 () 0.037 0.02 0.2 0.10
hsa-miR-19b mir-17 - mir-18a - mir-19a - mir-20a -
mir-19b-1 - mir-92a-1
13 90801447 . . . 90801533 () 0.040 76.36 15.37 4.97
hsa-miR-500 mir-532 - mir-188 - mir-500 - mir-362
- mir-501 - mir-660 - mir-502
X 49659779 . . . 49659862 () 0.040 0.18 0.94 0.19
hsa-miR-25 mir-106b - mir-93 - mir-25 7 99529119 . . . 99529202 () 0.044 21.30 7.91 2.69
Cluster’s, chromosome’s membership, and expression of each miRNA differentially expressed between MPM and HMCs.
ap value cutoff was 0.05, variance was not assumed equal (Welch t test), and it was applied the Benjamini and Hochberg False Discovery Rate multiple testing correction.
MPM, malignant pleura mesothelioma; HMCs, human normal pleural mesothelial short-term cell cultures; miRNA, microRNA.
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E2F activity after a physiologic proliferative signal, thereby
promoting cell division rather than cell death.15 This could
explain why miR-17-5p and its target, E2F1 mRNA, were
both up-regulated in our MPM samples. More recently, the
cyclin-dependent kinase inhibitor CDKN1A/p21 and the pro-
apoptotic gene BCL2L11/BIM have also been shown to be
targets of multiple members of the miR-17-92 cluster and
related miRNAs,13,43,44 which may act together to promote
cell cycle progression and, at the same time, evade Bim-
mediated apoptosis. Indeed, it has been shown that paralog
overexpression on chromosome 7 renders gastric cancer in-
sensitive to the transforming growth factor--mediated cell
cycle arrest, by interfering with CDKN1A/p21 expression13
and haploinsufficiency for Bim can accelerate lymphomagen-
esis in Eu-myc transgenic mice,45 similarly to miR-17-92
cluster overexpression, suggesting that this observed antiapo-
ptotic mechanism could possibly be related more to the
repression of Bim rather than E2F1. Importantly, miR-17-92
FIGURE 1. Cluster analysis of microRNA (miRNA) expression profiles in human normal pleural mesothelial short-term cell cul-
ture (HMC) and malignant pleura mesothelioma (MPM) cells. Cluster analysis obtained using the 22 miRNAs described in Ta-
ble 1, which exhibit at least a twofold differential expression between MPM and HCM samples, and which a p value 0.05
was applied to. The red color represents normal samples, whereas yellow represents tumors.
FIGURE 2. Expression of selected microRNAs
(miRNAs) in malignant pleura mesothelioma
(MPM) samples detected by reverse-transcriptase
quantitative polymerase chain reaction (RT-
qPCR) for microarray data validation. The miRNA
was determined by RT-qPCR assay in MPM sam-
ples. Data are expressed as a relative fold
change over the value of normal controls. Rela-
tive expression was calculated using the Ct
method, and the values are expressed as 2Ct.
As a normalization reference, U6 RNA was used.
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up-regulation may also increase tumor angiogenesis, by the
down-regulation of the antiangiogenic factors thrombospon-
din-1 (Tsp1) and connective tissue growth factor, both pre-
dicted targets of the miR-17-92 miRNAs.18 Thus, the over-
expression of members of miR-17-92 family may be involved
in MPM onset/development by promoting both initiating
cancer events, such as the induction of cell cycle progression
and cell survival, and progression steps, such as the angio-
genetic switch. On the other hand, CDKN2A/p16 which is
another cyclin-dependent kinase inhibitor has been shown to
be the target of other up-regulated miRNAs in MPM, includ-
ing miR-885-3p.46
A recent study reported on the expression of miRNAs
in three commercial cell lines, two MPM and one HMC. This
investigation reported that some members of onco-miRNA
miR-17-92 cluster and its paralog, such as miR-17-3p, miR-
17-5p, miR-18a, miR-20a, and miR-106a, and other miRNAs
related human tumorigenesis, such as miR-21, miR-29a, miR-
30b, miR-30c, andmiR-143,were up-regulated in MPM. Similar
results had previously been reported for other solid tumors,
including lung cancer.14,38 Our study reports miRNAs profiles of
primary cell cultures from freshly collected surgical specimens
and commercial cell lines. Our investigation reports for the first
time the dysregulation of miRNAs miR-25, miR-182, miR-339,
miR-7, miR-196b, miR-92, miR-19b, miR-20b, miR-106a, miR-
33, miR-500, miR-549, miR-22, miR-146b, miR-214, miR-502,
miR-497, and miR-328, whereas it confirms the dysregulation
of miRNAs miR-17-5p, miR-18a, miR-20a, and miR-106b, as
reported by Busacca et al.,38 but did not confirm the up-
regulation of miRNAs miR-17-3p, miR-29a, miR-30b, miR-
30c, miR-143,38 and miR-29c*.23 On the other hand, we
observed that miR-182 was markedly up-regulated in MPM in
agreement with what had been observed in polycythemia
vera.47 Similarly, miR-7 was up-regulated in MPM samples.
A recent investigation has reported on the involvement of
miR-7 in cell growth and apoptosis suggesting its potential
oncogenic role.48 Indeed, in a screening of about 200 miRNAs
for their ability to affect cell growth and apoptosis, miR-7
inhibition led to a decrease in cell growth by increasing the level
of apoptosis in HeLa cells.48 Conversely, miR-497 was down-
regulated in our MPM samples. Recently, this miRNA has been
found to be down-regulated in primary peritoneal carcinoma35
and in lung cancer34 CCND1 and CCND2 genes are among
the potential targets of miR-497.35 CCND2 protein is required
in cell cycles because it forms a complex and functions as a
regulatory subunit of CDK4 or CDK6, whose activity is
required for cell cycle G1/S transition. Moreover, it is in-
volved in the phosphorylation-mediated inactivation of tumor
FIGURE 3. Western Blot analysis of p21 protein. p21
expression in human normal pleural mesothelial short-
term cell culture and malignant pleura mesothelioma
samples. GAPDH was used as a reference gene.
TP53wild-type SKW6.4 cell line, treated with Nutlin-3 for
24 hours, was used as a WB-positive control for p21,
whereas the HeLa cell line was used for GAPDH. The
numbers below the figure represent the CDKN1A/p21
expression values obtained by microarray analysis (log2
transformed) and refer to the same samples.
TABLE 2. Expression of Selected miRNAs and Their Target Genes
miRNA
Fold Change
MPM/HMC
Regulation
MPM/HMC
miRNA Target
Gene Symbol
Fold Change MPM/HMC
(range 1.5–2.3)
Regulation
MPM/HMC
hsa-miR-17-5p 6.19 Up NCOA3 0.43 No variation
E2F1 7.41 Up
CDKN1A 9.50 Down
hsa-miR-19b 4.97 Up BACE1 10.61 Down
hsa-miR-20a 6.79 Up TGFBR2 1.97 No variation
hsa-miR-20b 6.91 Up MYLIP 3.00 Up
HIPK3 1.42 No variation
CDKN1A 9.50 Down
ARID4B 1.53 No variation
hsa-miR-106a 5.63 Up RB1 2.89 Down
MYLIP 3.00 Up
HIPK3 1.42 No variation
CDKN1A 9.50 Down
ARID4B 1.53 No variation
hsa-miR-106b 3.11 Up CDKN1A 9.50 Down
hsa-miR-214 902 Down PTEN 5.65 Down
Correlation between the expression of selected miRNAs and their target genes in MPM vs. HMCs.
MPM, malignant pleura mesothelioma; HMCs, human normal pleural mesothelial short-term cell cultures; miRNA, microRNA.
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suppressor pRb, as it is involved in the phosphorylation-
mediated inactivation of the tumor suppressor pRb via the
complex cyclin D/CdK4.49 Thus, the down-regulation of
miR-497 may lead to the presence of high CCND2 levels,
pRb inactivation and consequently uncontrolled cell prolifer-
ation, suggesting a potential tumor suppressor role for this
miR. It is interesting to note that the RB1 gene, which
encodes for pRB, was a target of up-regulated miR-106a and,
consequently, RB1 mRNA/pRb resulted underexpressed in
our MPM samples. These miRNAs could be involved in the
same pathway as regulates pRb expression and leads to
uncontrolled MPM progression.
In our MPM samples, miR-214 was found to be down-
regulated, whereas previous studies have reported its up-
regulation in ovarian cancer. In fact, a recent study has
investigated the role of miR-214 in human ovarian cancer and
has demonstrated that phosphate and tensin homolog 9
(PTEN) is targeted by this miR.50 PTEN is a ubiquitous tumor
suppressor gene that encodes for PTEN protein, which is very
important in the negative regulation of the Akt/PKB signaling
pathway. Loss of functional PTEN leads to increased Akt
activity and the mammalian target of rapamycin kinase path-
ways, which can promote both cell survival and proliferation
through phosphorylation and the inactivation of several
downstream mediators.51 In our MPM samples, PTEN
mRNA was detected as down-regulated, as was miR-214
(Table 2). This discrepancy can be explained by the fact that
different miRNAs have the potential ability to modulate the
expression of the same mRNA. Indeed, PTEN is a target not
only for miR-214 but also for miR-21,52 which exhibited a
1.3-fold change when the average expression of MPM cells
was compared with that of the HMCs in our analysis. Thus,
low levels of PTEN mRNA in our tumor samples could be
due to an overexpression of miR-21, as has been detected in
another study.52
The miRNAs that were found to be dysregulated in this
study could be proposed as specific MPM markers. Indeed,
other studies have identified these miRNAs, namely miR-17-
5p, miR-18a, miR-20a, and miR-106a, in MPM. These spe-
cific dysregulated miRNAs could be candidate makers for
MPM. Indeed, it turned out that recently proposed MPM
markers, such as osteopontin53 is a marker in common with
other human malignancies,54 whereas mesothelin55,56 is a
marker of asbestos exposure.57 MiRNAs, which were dys-
regulated in our MPM samples, may also represent potential
targets for new therapeutic approaches. The use of anti-
miRNA oligonucleotides or the reintroduction of the absent
miRNA could be a new therapeutic approach. In fact, the use
of anti-miRNA oligonucleotide in vivo has proven to be
feasible and has achieved long lasting miRNA activity
repression,58 whereas the reintroduction of miR-31 sup-
pressed the cell cycle and inhibited expression of multiple
factors involved in cooperative maintenance of DNA rep-
lication and cell cycle progression.24 Although further
studies are still needed, the identification of miRNA on-
cogenic targets in MPM could represent important infor-
mation for the development of new unconventional thera-
pies against this fatal disease.
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